{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:14:20Z","timestamp":1794474860995,"version":"4.9.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41582-025-01112-8","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T06:54:51Z","timestamp":1750834491000},"page":"422-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Neurological complications of CAR T cell therapy for cancers"],"prefix":"10.1038","volume":"21","author":[{"given":"Philipp","family":"Karschnia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-0136","authenticated-orcid":false,"given":"J\u00f6rg","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"1112_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR3","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR4","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR6","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi, B. D. et al. Intraventricular CARv3-TEAM-E T Cells in recurrent glioblastoma. N. Engl. J. Med. 390, 1290\u20131298 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004475","volume":"10","author":"K Rejeski","year":"2022","unstructured":"Rejeski, K. et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J. Immunother. Cancer 10, e004475 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1112_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"1112_CR11","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia, P. et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 133, 2212\u20132221 (2019).","journal-title":"Blood"},{"key":"1112_CR12","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jamaneurol.2024.2506","volume":"81","author":"JA Gudera","year":"2024","unstructured":"Gudera, J. A., Baehring, J. M. & Karschnia, P. Parkinsonism following chimeric antigen receptor T cell therapy. JAMA Neurol. 81, 1223\u20131224 (2024).","journal-title":"JAMA Neurol."},{"key":"1112_CR13","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1093\/neuonc\/noad118","volume":"25","author":"P Karschnia","year":"2023","unstructured":"Karschnia, P. et al. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells. Neuro Oncol. 25, 2239\u20132249 (2023).","journal-title":"Neuro Oncol."},{"key":"1112_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"1112_CR15","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","volume":"26","author":"CE Graham","year":"2025","unstructured":"Graham, C. E. et al. Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Lancet Oncol. 26, e203\u2013e213 (2025).","journal-title":"Lancet Oncol."},{"key":"1112_CR16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.2023020571","volume":"142","author":"P Karschnia","year":"2023","unstructured":"Karschnia, P. et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood 142, 1243\u20131248 (2023).","journal-title":"Blood"},{"key":"1112_CR17","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320\u20131329 (2024).","journal-title":"Nat. Med."},{"key":"1112_CR18","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.19.03279","volume":"38","author":"NN Shah","year":"2020","unstructured":"Shah, N. N. et al. CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J. Clin. Oncol. 38, 1938\u20131950 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1112_CR19","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat. Med. 28, 2145\u20132154 (2022).","journal-title":"Nat. Med."},{"key":"1112_CR20","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1182\/bloodadvances.2024013239","volume":"8","author":"F Furqan","year":"2024","unstructured":"Furqan, F. et al. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 8, 4320\u20134329 (2024).","journal-title":"Blood Adv."},{"key":"1112_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","volume":"28","author":"SJ Grant","year":"2022","unstructured":"Grant, S. J. et al. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transpl. Cell Ther. 28, 294\u2013302 (2022).","journal-title":"Transpl. Cell Ther."},{"key":"1112_CR22","doi-asserted-by":"crossref","unstructured":"First-ever CAR T-cell therapy approved in U.S. Cancer Discov. 7, OF1 (2017).","DOI":"10.1158\/2159-8290.CD-NB2017-126"},{"key":"1112_CR23","doi-asserted-by":"publisher","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust, J., Ponce, R., Liles, W. C., Garden, G. A. & Turtle, C. J. Cytokines in CAR T cell-associated neurotoxicity. Front. Immunol. 11, 577027 (2020).","journal-title":"Front. Immunol."},{"key":"1112_CR24","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8, 958\u2013971 (2018).","journal-title":"Cancer Discov."},{"key":"1112_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126\u2013142.e17 (2020).","journal-title":"Cell"},{"key":"1112_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000533","volume":"5","author":"P Karschnia","year":"2021","unstructured":"Karschnia, P. et al. Clinicopathologic findings in fatal neurotoxicity after adoptive immunotherapy with CD19-directed CAR T-cells. Hemasphere 5, e533 (2021).","journal-title":"Hemasphere"},{"key":"1112_CR27","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3324\/haematol.2022.281110","volume":"108","author":"SC Berger","year":"2023","unstructured":"Berger, S. C. et al. Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy. Haematologica 108, 444\u2013456 (2023).","journal-title":"Haematologica"},{"key":"1112_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"1112_CR29","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/s43018-024-00764-7","volume":"5","author":"JM Vinnakota","year":"2024","unstructured":"Vinnakota, J. M. et al. Targeting TGF\u03b2-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat. Cancer 5, 1227\u20131249 (2024).","journal-title":"Nat. Cancer"},{"key":"1112_CR30","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","volume":"6","author":"F Schoeberl","year":"2022","unstructured":"Schoeberl, F. et al. Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment. Blood Adv. 6, 3022\u20133026 (2022).","journal-title":"Blood Adv."},{"key":"1112_CR31","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1001\/jamaoncol.2022.3738","volume":"8","author":"OH Butt","year":"2022","unstructured":"Butt, O. H. et al. Assessment of pretreatment and posttreatment evolution of neurofilament light chain levels in patients who develop immune effector cell-associated neurotoxicity syndrome. JAMA Oncol. 8, 1652\u20131657 (2022).","journal-title":"JAMA Oncol."},{"key":"1112_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1212\/WNL.0000000000201083","volume":"99","author":"R Ursu","year":"2022","unstructured":"Ursu, R. et al. Long-term neurological safety in B-cell lymphoma patients treated with anti-CD19 CAR T-cell therapy. Neurology 99, 511\u2013515 (2022).","journal-title":"Neurology"},{"key":"1112_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/neuonc\/noab174","volume":"24","author":"I Beuchat","year":"2022","unstructured":"Beuchat, I. et al. EEG findings in CAR T-cell-associated neurotoxicity: clinical and radiological correlations. Neuro Oncol. 24, 313\u2013325 (2022).","journal-title":"Neuro Oncol."},{"key":"1112_CR34","volume":"5","author":"S Stoecklein","year":"2023","unstructured":"Stoecklein, S. et al. Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity. Neurooncol. Adv. 5, vdad135 (2023).","journal-title":"Neurooncol. Adv."},{"key":"1112_CR35","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404\u20131419 (2017).","journal-title":"Cancer Discov."},{"key":"1112_CR36","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi, J. et al. Tumor inflammation-associated neurotoxicity. Nat. Med. 29, 803\u2013810 (2023).","journal-title":"Nat. Med."},{"key":"1112_CR37","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41577-021-00508-z","volume":"21","author":"AF Salvador","year":"2021","unstructured":"Salvador, A. F., de Lima, K. A. & Kipnis, J. Neuromodulation by the immune system: a focus on cytokines. Nat. Rev. Immunol. 21, 526\u2013541 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1112_CR38","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1200\/JCO.23.02019","volume":"42","author":"FY Lin","year":"2024","unstructured":"Lin, F. Y. et al. Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors. J. Clin. Oncol. 42, 2769\u20132779 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1112_CR39","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2024","unstructured":"Monje, M. et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature 637, 708\u2013715 (2024).","journal-title":"Nature"},{"key":"1112_CR40","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMc1704610","volume":"377","author":"JS Abramson","year":"2017","unstructured":"Abramson, J. S. et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N. Engl. J. Med. 377, 783\u2013784 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR41","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","volume":"186","author":"F Winkler","year":"2023","unstructured":"Winkler, F. et al. Cancer neuroscience: state of the field, emerging directions. Cell 186, 1689\u20131707 (2023).","journal-title":"Cell"},{"key":"1112_CR42","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-021-04082-1","volume":"599","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. B cell-derived GABA elicits IL-10+ macrophages to limit anti-tumour immunity. Nature 599, 471\u2013476 (2021).","journal-title":"Nature"},{"key":"1112_CR43","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"1112_CR44","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265\u20131274 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1112_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen, A. D. et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 12, 32 (2022).","journal-title":"Blood Cancer J."},{"key":"1112_CR46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1369\/00221554221079579","volume":"70","author":"M Marella","year":"2022","unstructured":"Marella, M. et al. Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-targeting multiple myeloma therapy. J. Histochem. Cytochem. 70, 273\u2013287 (2022).","journal-title":"J. Histochem. Cytochem."},{"key":"1112_CR47","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood.2023021429","volume":"142","author":"CE Graham","year":"2023","unstructured":"Graham, C. E. et al. Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood 142, 1248\u20131252 (2023).","journal-title":"Blood"},{"key":"1112_CR48","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/jnnp.2003.011874","volume":"75","author":"F Alarc\u00f3n","year":"2004","unstructured":"Alarc\u00f3n, F., Zijlmans, J. C., Due\u00f1as, G. & Cevallos, N. Post-stroke movement disorders: report of 56 patients. J. Neurol. Neurosurg. Psychiatry 75, 1568\u20131574 (2004).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1112_CR49","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1182\/blood.2023021860","volume":"142","author":"J Gust","year":"2023","unstructured":"Gust, J. BCMA-CAR T-cell treatment-associated parkinsonism. Blood 142, 1181\u20131183 (2023).","journal-title":"Blood"},{"key":"1112_CR50","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2023-178743","volume":"142","author":"NWCJ Van De Donk","year":"2023","unstructured":"Van De Donk, N. W. C. J. et al. Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel). Blood 142, 3501 (2023).","journal-title":"Blood"},{"key":"1112_CR51","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/19418744231167290","volume":"13","author":"N Patrick","year":"2023","unstructured":"Patrick, N., Bahlis, N. & Peters, S. Chimeric antigen receptor-T cell mediated bilateral facial nerve palsy: a case report. Neurohospitalist 13, 308\u2013311 (2023).","journal-title":"Neurohospitalist"},{"key":"1112_CR52","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3324\/haematol.2023.283296","volume":"109","author":"YK Kathari","year":"2024","unstructured":"Kathari, Y. K. et al. Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells. Haematologica 109, 682\u2013688 (2024).","journal-title":"Haematologica"},{"key":"1112_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006059","volume":"11","author":"C Koch","year":"2023","unstructured":"Koch, C. et al. Diabetes insipidus and Guillain-Barr\u00e9-like syndrome following CAR-T cell therapy: a case report. J. Immunother. Cancer 11, e006059 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1112_CR54","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3324\/haematol.2020.259952","volume":"106","author":"R Nair","year":"2021","unstructured":"Nair, R. et al. Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica 106, 1504\u20131506 (2021).","journal-title":"Haematologica"},{"key":"1112_CR55","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jha2.286","volume":"3","author":"S Sheikh","year":"2022","unstructured":"Sheikh, S. et al. Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. eJHaem 3, 223\u2013227 (2022).","journal-title":"eJHaem"},{"key":"1112_CR56","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1182\/blood.2024025679","volume":"144","author":"X Desch\u00eanes-Simard","year":"2024","unstructured":"Desch\u00eanes-Simard, X., Santomasso, B. D. & Dahi, P. B. Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy. Blood 144, 2083\u20132094 (2024).","journal-title":"Blood"},{"key":"1112_CR57","first-page":"2443","volume":"141","author":"BD Santomasso","year":"2023","unstructured":"Santomasso, B. D., Gust, J. & Perna, F. How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity. Blood 141, 2443\u20132451 (2023).","journal-title":"Blood"},{"key":"1112_CR58","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.21873\/invivo.12640","volume":"35","author":"M Kuboki","year":"2021","unstructured":"Kuboki, M. et al. Severe motor weakness due to disturbance in peripheral nerves following tisagenlecleucel treatment. In Vivo 35, 3407\u20133411 (2021).","journal-title":"In Vivo"},{"key":"1112_CR59","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1002\/ajh.27505","volume":"99","author":"LD Kaulen","year":"2024","unstructured":"Kaulen, L. D. et al. Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis. Am. J. Hematol. 99, 2411\u20132415 (2024).","journal-title":"Am. J. Hematol."},{"key":"1112_CR60","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1056\/NEJMra1209390","volume":"370","author":"JP Kress","year":"2014","unstructured":"Kress, J. P. & Hall, J. B. ICU-acquired weakness and recovery from critical illness. N. Engl. J. Med. 370, 1626\u20131635 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005459","volume":"10","author":"Y Amidi","year":"2022","unstructured":"Amidi, Y. et al. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. J. Immunother. Cancer 10, e005459 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1112_CR62","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","volume":"77","author":"DB Rubin","year":"2020","unstructured":"Rubin, D. B. et al. Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy. JAMA Neurol. 77, 1536\u20131542 (2020).","journal-title":"JAMA Neurol."},{"key":"1112_CR63","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1182\/bloodadvances.2024014027","volume":"9","author":"D Zandaki","year":"2025","unstructured":"Zandaki, D. et al. EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy. Blood Adv. 9, 270\u2013279 (2025).","journal-title":"Blood Adv."},{"key":"1112_CR64","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi, M. et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 5, 3397\u20133406 (2021).","journal-title":"Blood Adv."},{"key":"1112_CR65","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00277-024-05617-y","volume":"103","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Modified EASIX scores predict severe CRS\/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy. Ann. Hematol. 103, 969\u2013980 (2024).","journal-title":"Ann. Hematol."},{"key":"1112_CR66","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","volume":"7","author":"C Roddie","year":"2023","unstructured":"Roddie, C. et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 7, 2872\u20132883 (2023).","journal-title":"Blood Adv."},{"key":"1112_CR67","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1182\/bloodadvances.2023012549","volume":"8","author":"N Ahmed","year":"2024","unstructured":"Ahmed, N. et al. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 8, 5346\u20135354 (2024).","journal-title":"Blood Adv."},{"key":"1112_CR68","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ejca.2020.11.021","volume":"144","author":"SF Winter","year":"2021","unstructured":"Winter, S. F., Martinez-Lage, M., Clement, N. F., Hochberg, E. P. & Dietrich, J. Fatal neurotoxicity after chimeric antigen receptor T-cell therapy: an unexpected case of fludarabine-associated progressive leukoencephalopathy. Eur. J. Cancer 144, 178\u2013181 (2021).","journal-title":"Eur. J. Cancer"},{"key":"1112_CR69","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJMra2401857","volume":"391","author":"CM Tanner","year":"2024","unstructured":"Tanner, C. M. & Ostrem, J. L. Parkinson\u2019s disease. N. Engl. J. Med. 391, 442\u2013452 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR70","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(04)16508-2","volume":"363","author":"JD England","year":"2004","unstructured":"England, J. D. & Asbury, A. K. Peripheral neuropathy. Lancet 363, 2151\u20132161 (2004).","journal-title":"Lancet"},{"key":"1112_CR71","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso, B. D. et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J. Clin. Oncol. 39, 3978\u20133992 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1112_CR72","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","volume":"32","author":"J Gust","year":"2018","unstructured":"Gust, J., Taraseviciute, A. & Turtle, C. J. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs 32, 1091\u20131101 (2018).","journal-title":"CNS Drugs"},{"key":"1112_CR73","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jtct.2024.08.018","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke, F. L. et al. Tocilizumab prophylaxis following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Transpl. Cell Ther. 30, 1065\u20131079 (2024).","journal-title":"Transpl. Cell Ther."},{"key":"1112_CR74","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain, M. D., Smith, M. & Shah, N. N. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 141, 2430\u20132442 (2023).","journal-title":"Blood"},{"key":"1112_CR75","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","volume":"4","author":"P Strati","year":"2020","unstructured":"Strati, P. et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 4, 3123\u20133127 (2020).","journal-title":"Blood Adv."},{"key":"1112_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003847","volume":"10","author":"M Wehrli","year":"2022","unstructured":"Wehrli, M. et al. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J. Immunother. Cancer 10, e003847 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1112_CR77","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","volume":"29","author":"N Gazeau","year":"2023","unstructured":"Gazeau, N. et al. Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transpl. Cell Ther. 29, 430\u2013437 (2023).","journal-title":"Transpl. Cell Ther."},{"key":"1112_CR78","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamaoncol.2022.0070","volume":"8","author":"JC Zurko","year":"2022","unstructured":"Zurko, J. C. et al. Use of early intrathecal therapy to manage high-grade immune effector cell-associated neurotoxicity syndrome. JAMA Oncol. 8, 773\u2013775 (2022).","journal-title":"JAMA Oncol."},{"key":"1112_CR79","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1182\/bloodadvances.2020001626","volume":"4","author":"NN Shah","year":"2020","unstructured":"Shah, N. N., Johnson, B. D., Fenske, T. S., Raj, R. V. & Hari, P. Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. Blood Adv. 4, 2119\u20132122 (2020).","journal-title":"Blood Adv."},{"key":"1112_CR80","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","volume":"3","author":"SR Bailey","year":"2022","unstructured":"Bailey, S. R. et al. Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discov. 3, 136\u2013153 (2022).","journal-title":"Blood Cancer Discov."},{"key":"1112_CR81","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/bloodadvances.2024013688","volume":"9","author":"A Bajwa","year":"2024","unstructured":"Bajwa, A. et al. Siltuximab for chimeric antigen receptor T-cell therapy related CRS and ICANS \u2014 a multicenter retrospective analysis. Blood Adv. 9, 170\u2013175 (2024).","journal-title":"Blood Adv."},{"key":"1112_CR82","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00415-019-09666-6","volume":"267","author":"M Chung","year":"2020","unstructured":"Chung, M. et al. Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange. J. Neurol. 267, 1023\u20131025 (2020).","journal-title":"J. Neurol."},{"key":"1112_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001114","volume":"8","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. J. Immunother. Cancer 8, e001114 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1112_CR84","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber, E. W. et al. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 3, 711\u2013717 (2019).","journal-title":"Blood Adv."},{"key":"1112_CR85","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/jcmm.16176","volume":"25","author":"J Pan","year":"2021","unstructured":"Pan, J. et al. Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy. J. Cell Mol. Med. 25, 1089\u20131099 (2021).","journal-title":"J. Cell Mol. Med."},{"key":"1112_CR86","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1182\/blood-2023-187070","volume":"142","author":"N Sumransub","year":"2023","unstructured":"Sumransub, N. et al. Simvastatin with intrathecal dexamethasone reduces neurotoxicity in adults receiving chimeric antigen receptor (CAR) T-cells treatment. Blood 142, 3493 (2023).","journal-title":"Blood"},{"key":"1112_CR87","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1182\/blood.2024028172","volume":"145","author":"V Blumenberg","year":"2025","unstructured":"Blumenberg, V. et al. Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment. Blood 145, 2788\u20132793 (2025).","journal-title":"Blood"},{"key":"1112_CR88","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1182\/blood.2021014738","volume":"139","author":"MJ Frigault","year":"2022","unstructured":"Frigault, M. J. et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial. Blood 139, 2306\u20132315 (2022).","journal-title":"Blood"},{"key":"1112_CR89","doi-asserted-by":"publisher","first-page":"780","DOI":"10.14245\/ns.2244196.098","volume":"19","author":"SH Park","year":"2022","unstructured":"Park, S. H. et al. Pathological classification of the intramedullary spinal cord tumors according to 2021 World Health Organization classification of central nervous system tumors, a single-institute experience. Neurospine 19, 780\u2013791 (2022).","journal-title":"Neurospine"},{"key":"1112_CR90","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","volume":"29","author":"JH Park","year":"2023","unstructured":"Park, J. H. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat. Med. 29, 1710\u20131717 (2023).","journal-title":"Nat. Med."},{"key":"1112_CR91","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1182\/bloodadvances.2023010653","volume":"7","author":"P Strati","year":"2023","unstructured":"Strati, P. et al. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv. 7, 6785\u20136789 (2023).","journal-title":"Blood Adv."},{"key":"1112_CR92","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673\u20131683 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1112_CR93","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","volume":"124","author":"B Philip","year":"2014","unstructured":"Philip, B. et al. A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy. Blood 124, 1277\u20131287 (2014).","journal-title":"Blood"},{"key":"1112_CR94","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying, Z. et al. A safe and potent anti-CD19 CAR T cell therapy. Nat. Med. 25, 947\u2013953 (2019).","journal-title":"Nat. Med."},{"key":"1112_CR95","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.coi.2021.07.002","volume":"74","author":"AC Sahillioglu","year":"2022","unstructured":"Sahillioglu, A. C. & Schumacher, T. N. Safety switches for adoptive cell therapy. Curr. Opin. Immunol. 74, 190\u2013198 (2022).","journal-title":"Curr. Opin. Immunol."},{"key":"1112_CR96","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1182\/bloodadvances.2024013044","volume":"8","author":"F Perna","year":"2024","unstructured":"Perna, F. et al. CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations. Blood Adv. 8, 4348\u20134358 (2024).","journal-title":"Blood Adv."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01112-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01112-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01112-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:50:55Z","timestamp":1757206255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01112-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":96,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1038\/s41582-025-01112-8","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"6 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.K. has served as a consultant for the American Society of Clinical Oncology. J.D. has served as a consultant and on advisory boards for Amgen, Novartis, Janssen and Johnson & Johnson. He has received research support from Ono Pharmaceuticals and royalties from Wolters Kluwer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}